Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial

Urology

Volumn 50, Issue 3, 1997, Pages 330-336

  Schellhammer, Paul F ^a   Sharifi, Roohollah ^b   Block, Norman L ^b   Soloway, Mark S ^b   Venner, Peter M ^b   Patterson, A Lynn ^b   Sarosdy, Michael F ^b   Vogelzang, Nicholas J ^b   Schellenger, Julie Jones ^b   Kolvenbag, Geert J C M ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GONADORELIN; GOSERELIN; LEUPRORELIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HORMONAL REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOUBLE-BLIND METHOD; FLUTAMIDE; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0030824059     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00279-3     Document Type: Article

References (22)

1. Gilles RF: Carcinoma of the prostate. N Engl J Med 324: 236-245, 1991.
2. Prostate Cancer Trialists' Collaborative Group: Maximal androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 346: 265-269, 1995.
3. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989.
4. 2 prostate cancer: important implications for future trials: results of a cooperative group study (INT.0036). Semin Oncol 21: 613-619, 1994.
5. Denis L, Smith PH, Carneiro de Moura JL, Newling DWW, Bono A, Keuppens F, Robinson M, Mahler C, Sylvester R, Depauw M, et al: Orchiectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. Eur Urol 18(suppl 3): 34-40, 1990.
6. Denis LJ, Carneiro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, and Depauw M: Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42: 119-130, 1993.
7. Janknegt RA, for the Anandron International Study Group: Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Cancer 72(suppl): 3874-3877, 1993.
8. 2 adenocarcinoma of the prostate (CaP): results of NCI Intergroup study 0105 (SWOG and ECOG). J Urol 157(suppl): 336, 1997.
9. Delaere KPJ, and Van Thillo EL: Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 18(suppl 6): 13-18, 1991.
10. Lundgren R: Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol 59: 156-158, 1987.
11. Tyrrell CJ, Altwein JE, Klippel F, Varenhorst E, Lunglmayr G, Boccardo F, Holdaway IM, Haefliger JM, Jordaan JP, and Sotarauta M: A multicentre randomized trial comparing 'Zoladex' with 'Zoladex' + flutamide in the treatment of advanced prostate cancer (survival update), in Murphy G, Khoury S, Chatelain C, and Denis L (Eds): Proceedings of the 3rd International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment, June 17-19, 1992. Paris, France, 1993, pp 98-101.
12. Iversen P, Christensen MG, Friis E, Hornbol P, Hvidt V, Iversen HG, Klarskov P, Krarup T, Lund F, Mogensen P, et al: A phase III trial of Zoladex and flutamide versus orchidectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 66 (suppl 5): 1058-1066, 1990.
13. Boccardo F, Decensi A, Guarneri D, Rubagotti A, Oneto F, Martorana G, Giuliani L, Delli Ponti U, Petracco S, and Cortellini P: Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Eur Urol 18(suppl 3): 48-53, 1990.
14. Boccon-Gibod L, Fournier G, Bottet P, and Mallo C: Flutamide versus orchiectomy in patients with metastatic prostatic carcinoma. J Urol 147(suppl): 417A, 1992.
15. Rosenthal SA, Linstadt DE, Leibenhaut MH, Andras EJ, Brooks CP, Stickney DR, Chang GC, Wolkov HB, and Gilbert RM: Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Radiology 199: 451-455, 1996.
16. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G, for the CASODEX Combination Study Group: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45: 745-752, 1995.
17. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G, for the CASODEX Combination Study Group: Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Urology 47(suppl 1A): 54-60, 1996.
18. Schellhammer PF, Sharifi R, Block NL, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Chen Y, Kolvenbag GJCM, for the CASODEX Combination Study Group: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone releasing hormone analogue therapy, in patients with advanced prostate cancer: analysis of time to progression. Cancer 78: 2164-2169, 1996.
19. Narayan P, Trachtenberg J, Lepor H, Debruyne FMJ, Tewari A, Stone N, Das S, Jimenez-Cruz JF, Shearer R, Klimberg I, Schellhammer PF, and Costello AJ: A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. Urology 47: 497-504, 1996.
20. Schellhammer P: Bicalutamide as an alternative for advanced PCa. Contemp Urol 8: 31-35, 1996.
21. McLeod D: Tolerability of non-steroidal antiandrogens. The Oncologist 2: 18-27, 1997.
22. Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh R, Patterson AL, Klein E, Wajsman Z, Furr B, et al: Prostate-specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157: 1731-1735, 1997.